Axial Spondyloarthritis (axSpA) Treatment Market Size
Market Size in USD Bn
CAGR7.7%
| Study Period | 2025-2032 |
| Base Year of Estimation | 2024 |
| CAGR | 7.7% |
| Market Concentration | High |
| Major Players | AbbVie Inc., Novartis AG, Pfizer Inc., UCB Pharma, Eli Lilly and Company and Among Others |
*Disclaimer: Major players are listed in no particular order.
*Source: Coherent Market Insights
Want to purchase customized report?
please let us know !
please let us know !
Axial Spondyloarthritis (axSpA) Treatment Market Analysis
The axial spondyloarthritis (axSpA) treatment market is estimated to be valued at USD 6.48 billion in 2025 and is expected to reach USD 10.89 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.7% from 2025 to 2032. Increased prevalence of axSpA and rising population are major drivers responsible for growth of this market. Additionally, development and launch of novel biologic therapies for axSpA treatment such as IL-23 and IL-17 inhibitors have boosted the market growth over the past years.